Analgesics and beyond: Time-release delivery firm looks for investment

By Dan Stanton contact

- Last updated on GMT


Related tags: Drug delivery, Initial public offering

InSitu Biologics says it is looking for investors to support its hydrogel-based drug delivery system AnestaGel.

The Minnesota-based firm has developed an implantable time-release drug delivery device it is using with a non-opioid analgesic for perioperative pain management. To move the product into the clinic the firm is hoping to raise $1m through a regulation D stock offering,

According to the firm, AnestaGel is composed of a proprietary tunable, bio-polymeric hydrogel, which “essentially acts as a non-pulsatile organ, providing sustained drug release for a pre-determined length of time.”

According to an InSitu spokesperson, “the underlying technology is biocompatible and pH neutral, allowing AnestaGel to potentially provide target site-specific, non-migratory placement and deliver immediate, long-lasting pain relief.”

In preclinical studies, the delivery system has demonstrated a longer lasting and greater analgesic effect than Exparel (bupivacaine), a local anaesthetic marketed by Pacira Pharmaceuticals.

While the firm’s short-term goals include completing extensive Phase I clinical testing, InSitu is also hoping to use money raised for a subsequent Regulation A+ offering as an alternative to an initial public offering (IPO) to go public.

The firm’s long-term goal is to bring the AnestaGel system through the commercialisation process through a marketing partner or, according to the spokesperson, even by being acquired.

The base biohydrogel material is licensed from the Cleveland Clinic Foundation, but the company has created additional Intellectual Property relating to the crosslinking technology, tunability of the gel, and drug delivery applications.

“In addition to creating the non-opioid AnestaGel, we believe that the Matrix can be used in a myriad of fields, providing sustained release for hundreds of known, and yet to be discovered molecules,”​ the firm said.

Related news

Show more

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Local lab Data Management

Local lab Data Management

Q² Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Related suppliers

Follow us


View more